Eledon Pharmaceuticals Achieves Insulin Independence in Diabetes Patients Through Islet Transplant Trial
Eledon Pharmaceuticals has reported significant progress in its islet transplant trial for type 1 diabetes patients. The trial, conducted at UChicago Medicine, involved 12 patients, with 10 achieving insulin independence more than four weeks post-transplant. The mean HbA1c level among these patients was approximately 5.35%, indicating effective blood sugar control. The trial utilized tegoprubart, a drug aimed at protecting islet grafts without the toxicities associated with traditional calcineurin inhibitors. This development is part of Eledon's broader efforts to advance tegoprubart across various transplantation and disease areas, including kidney and liver allografts, xenotransplantation, and ALS. The company is seeking regulatory guidance from the FDA to potentially bring tegoprubart to market for islet cell transplantation later this year. 
